Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegafur + gimeracil + oteracil potassium + cisplatin + everolimus
- Development stage
- Unknown
- Lead developer
- National University Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TS-ONE + cisplatin + RAD001 is an investigational combination therapy regimen being evaluated for the treatment of refractory solid malignancies, including gastric cancer. The regimen consists of three primary components: TS-1 (a fixed-dose combination of the 5-fluorouracil prodrug tegafur, the dihydropyrimidine dehydrogenase inhibitor gimeracil, and the orotate phosphoribosyltransferase inhibitor oteracil potassium), the platinum-based cytotoxic agent cisplatin, and the mTOR inhibitor everolimus (RAD001). The combination aims to leverage the synergistic effects of mTOR inhibition with traditional chemotherapy to overcome treatment resistance and improve clinical outcomes in patients who have failed prior therapies. Preclinical data suggests that the addition of everolimus can sensitize tumor cells to cisplatin and fluoropyrimidines by inhibiting survival pathways frequently upregulated in resistant cancers.
- Brand names
- TeysunoAfinitor
- Other names
- TS-ONE + cisplatin + RAD001S-1 + cisplatin + everolimusTS-1 + CDDP + everolimus
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)TS (Thymidylate synthase)mTOR (Mammalian target of rapamycin kinase)DNAOPRT (Orotidine 5'-phosphate decarboxylase)
Beyond the preview
Go deeper on tegafur + gimeracil + oteracil potassium + cisplatin + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegafur + gimeracil + oteracil potassium + cisplatin + everolimus.